[en] In the management of beta-thalassaemia major, different transfusion schemes are employed with baseline haemoglobin levels ranging from 8 to over 12 g/dl. We studied the relationship between transfusion regimen and suppression of erythropoiesis in 52 patients with beta-thalassaemia major whose mean pretransfusion haemoglobin levels ranged from 8.6 to 10.9 g/dl. Multiple, regression analysis showed that serum transferrin receptor was the parameter more closely related to mean pretransfusion haemoglobin (r = -0.77, P < 0.001). As measured through serum transferrin receptor, erythroid activity was 1-2 times normal for pretransfusion haemoglobin levels between 10 and 11 g/dl. 1-4 times normal for levels from 9 to 10 g/dl, and 2-6 times normal for levels from 8.6 to 9 g/dl. Mean pretransfusion haemoglobin was also inversely related to serum erythropoietin (r = -0.72, P < 0.001), whereas it showed no or a weak relationship with Hb F, reticulocyte count, or circulating nucleated red cell count. This study suggests that serum transferrin receptor is a reliable indicator of suppression of erythropoiesis in beta-thalassaemia major. On the basis of our findings, pretransfusion haemoglobin values of < or = 9 g/dl should be adopted with caution, because these levels can be associated with an insufficient inhibition of erythroid marrow expansion. However, a transfusion programme, with a baseline haemoglobin of 9-10 g/dl, may provide enough suppression of erythropoiesis and allow a reduction in blood consumption as compared with the classic hyper- or supertransfusion schemes. Since fixed haemoglobin levels may not be the best target for transfusion treatment in all thalassaemic patients, assay of serum transferrin receptor may be helpful for individualizing the transfusion regimens.
Disciplines :
Hematology
Author, co-author :
Cazzola, M.
De Stefano, P.
Ponchio, L.
Locatelli, F.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Dessi, C.
Barella, S.
Cao, A.
Galanello, R.
Language :
English
Title :
Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major.
André M., Bergmann P., Ferster A., Topper M., Fondu P. (1991) Serum immunoreactive erythropoietin level: a new parameter for monitoring transfusion management of thalassaemia. Nouvelle Revue Frančaise d'Hématologie 33:299-302.
Beguin Y., Clemons G.K., Pootrakul P., Fillet G. (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067-1076.
Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., Allen C.J., Farrell D.E., Harris J.W. (1994) Efficacy of deferoxamine in preventing complication of iron overload in patients with thalassemia major. New England Journal of Medicine 331:567-573.
Cavill I., Ricketts C., Jacobs A., Letsky E. (1978) Erythropoiesis and the effect of transfusion in homozygous β‐thalassemia. New England Journal of Medicine 298:776-778.
Cazzola M., Alessandrino P., Barosi G., Morandi S., Stefanelli M. (1979) Quantitative evaluation of the mechanisms of the anaemia in heterozygous β‐thalassaemia. Scandinavian Journal of Haematology 23:107-114.
Cazzola M., Alessandrino P., Barosi G., Orlandi E., Ascari E. (1980) Iron loading in β‐thalassaemia. (Letter). Lancet 1:204.
Cazzola M., Barosi G., Bergamaschi G., Dezza L., Palestra P., Polino G., Ramella S., Spriano P., Ascari E. (1983) Iron loading in congenital dyserythropopoietic anaemias and congenital sideroblastic anaemias. British Journal of Haematology 54:649-654.
Cazzola M., Beguin Y. (1992) New tools for clinical evaluation of erythropoiesis and iron status in man. British Journal of Haematology 80:278-284.
Cazzola M., De Stefano P., Locatelli F., Dessì C., Barella S., Beguin Y., Cao A., Galanello R. (1994) Relationship between transfusion regimen and suppression of erythropoiesis in β‐thalassaemia major. (Abstract). British Journal of Haematology , 59; 87.
Cazzola M., Pootrakul P., Huebers H.A., Eng M., Eschbach J., Finch C.A. (1987) Erythroid marrow function in anemic man. Blood 69:296-301.
Dore F., Bonfigli S., Gaviano E., Pardini S., Cianciulli P., Papa G., Longinotti M. (1993) Serum erythropoietin levels in thalassemia intermedia. Annals of Hematology 67:183-186.
Hillman R.S., Finch C.A., Red Cell Manual, 5th edn, F. A. Davis, Philadelphia; 1985.
Lucarelli G., Galimberti M., Polchi P., Angelucci E., Baronciani D., Giardini C., Politi P., Durazzi S.M.T., Muretto P., Albertini F. (1990) Bone marrow transplantation in patients with thalassemia. New England Journal of Medicine 322:417-421.
McDonagh K.T., Nienhuis A.W. (1993) The thalassemias. Hematology of Infancy and Childhood , ed. by, D. G. Nathan, F. A. Oski, Saunders, Philadelphia; 783-879.
Musto P., Lombardi G., Centra M., Modoni S., Carotenuto M., Di Giorgio G. (1993) Soluble transferrin receptor in beta‐thalassaemia. (Letter). Lancet 342:1058.
Olivieri N.F., Nathan D.G., MacMillan J., Wayne A.S., Liu P.P., McGee A., Martin M., Koren G., Cohen A.R. (1994) Survival in medically treated patients with homozygous β‐thalassemia. New England Journal of Medicine 331:574-578.
Piomelli S., Karpatkin M.H., Arzanian M., Zamani M., Becker M.H., Geneiser N., Danoff S.J., Kuhns W.J. (1974) Hypertransfusion regimen in patients with Cooley's anemia. Annals of the New York Academy of Sciences 232:186-192.
Pippard M.J., Callender S.T., Warner G.T., Weatherall D.J. (1977) Iron absorption in iron‐loading anaemias: effect of subcutaneous desferrioxamine infusions. Lancet 2:737-739.
Pootraku P., Hungsprenges S., Fucharoen S., Baylink D., Thompson E., English E., Lee M., Burnell J., Finch C.A. (1981) Relation between erythropoiesis and bone metabolism in thalassemia. New England Journal of Medicine 304:1470-1473.
Pootrakul P., Kitcharoen K., Yansukon P., Wasi P., Fucharoen S., Charoenlarp P., Brittenham G., Pippard M.J., Finch C.A. (1988) The effect of erythroid hyperplasia on iron balance. Blood 71:1124-1129.
Propper R.D., Button L.N., Nathan D.G. (1980) New approaches to the transfusion management of thalassemia. Blood 55:55-60.
Singhal A., Cook J.D., Skikne B.S., Thomas P., Serjeant B., Serjeant G. (1993) The clinical significance of serum transferrin receptor levels in sickle cell disease. British Journal of Haematology 84:301-304.